Screener
Amneal Pharmaceuticals, Inc. AMRX Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
FAQ
- What is Amneal Pharmaceuticals, Inc.'s total equity?
- Amneal Pharmaceuticals, Inc. (AMRX) reported total equity of $33.02M in Q2 2026.
- How has Amneal Pharmaceuticals, Inc.'s total equity changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s total equity increased by 129.5% year-over-year, from -$112.12M to $33.02M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s total equity?
- Over 5 years (2020 to 2025), Amneal Pharmaceuticals, Inc.'s total equity has grown at a -25.2% compound annual growth rate (CAGR), from $303.27M to -$70.79M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Amneal Pharmaceuticals, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude